We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
An image displaying a Newsletter on tablet, laptop & mobile

To continue reading this article, sign up for FREE to

Technology Networks logo


Membership is FREE and provides you with instant access to email newsletters, digital publications, our full content catalogue & more...

OGT Releases New Whitepaper for Aiding Biomarker Discovery

Read time: Less than a minute

Oxford Gene Technology (OGT) has released a new whitepaper entitled ‘Autoantibody biomarker panels for improved disease diagnosis’. The free-to-download document explores the need for biomarkers as indicators of disease, and discusses the vast potential of autoantibodies as markers of early disease development.

Autoantibodies are produced by the host immune system and as such are often detectable during the early stages of disease onset. In addition, they are stable, abundant, highly specific and easily purified from serum, making them ideal candidates for use in disease detection. The issues surrounding the use of autoantibodies as biomarkers are discussed in detail in the whitepaper, including their relative advantages, selection of the most appropriate discovery technology and choosing between strategies for in-house or outsourced discovery.

Google News Preferred Source Add Technology Networks as a preferred Google source to see more of our trusted coverage.